The systemic effects of sclerostin overexpression using Φc31 integrase in mice

Dongdong Zhang, Bo Mi Park, Myengmo Kang, Hee Jin Nam, Eun Jin Kim, Chu Hyun Bae, Sungkil Lim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sclerostin, encoded by the Sost gene, is mainly produced by osteocytes in bone and antagonizes the Wnt/β-catenin signaling pathway, which is a requisite for bone formation. Currently, human anti-sclerostin antibodies are being tested in phase III clinical trials. In addition, serum sclerostin levels are reported to be associated with bone mineral density and fracture risk in normal individuals; however, the correlation between serum sclerostin and bone mass remains controversial. To study the effects of the continuous exposure of exogenous sclerostin on bone, a ΦC31 integrase system, which has the characteristics of site-specificity and efficiency, was applied for the delivery of the Sost gene in this study. We injected Sost-attB plasmid with or without ΦC31 integrase plasmid into the mouse tail vein using a hydrodynamic-based method. The site-specific integration of the Sost gene into the mouse genome was confirmed by examining a pseudo-attP site on the hepatic genomic DNA. Sclerostin was expressed in the hepatocytes, secreted into the blood flow, and maintained at high concentrations in the mice with both Sost-attB plasmid and ΦC31 integrase plasmid injections, which was observed by serial measurement. Moreover, the mice with long-term high levels of serum sclerostin showed trabecular bone loss on micro-CT analysis. Peripheral B cell populations were not affected. Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the ΦC31 integrase system, leading to trabecular bone loss. These findings may help to further ascertain the effects of sclerostin introduced exogenously on the skeleton.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume472
Issue number3
DOIs
Publication statusPublished - 2016 Apr 8

Fingerprint

Integrases
Bone
Plasmids
Bone and Bones
Genes
Serum
Osteocytes
Catenins
Phase III Clinical Trials
Wnt Signaling Pathway
Liver
Bone Fractures
Hydrodynamics
Osteogenesis
Skeleton
Bone Density
Blood
Tail
Anti-Idiotypic Antibodies
Hepatocytes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Zhang, Dongdong ; Park, Bo Mi ; Kang, Myengmo ; Nam, Hee Jin ; Kim, Eun Jin ; Bae, Chu Hyun ; Lim, Sungkil. / The systemic effects of sclerostin overexpression using Φc31 integrase in mice. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 472, No. 3. pp. 471-476.
@article{4204824d09f645abae36045c0c6ac086,
title = "The systemic effects of sclerostin overexpression using Φc31 integrase in mice",
abstract = "Sclerostin, encoded by the Sost gene, is mainly produced by osteocytes in bone and antagonizes the Wnt/β-catenin signaling pathway, which is a requisite for bone formation. Currently, human anti-sclerostin antibodies are being tested in phase III clinical trials. In addition, serum sclerostin levels are reported to be associated with bone mineral density and fracture risk in normal individuals; however, the correlation between serum sclerostin and bone mass remains controversial. To study the effects of the continuous exposure of exogenous sclerostin on bone, a ΦC31 integrase system, which has the characteristics of site-specificity and efficiency, was applied for the delivery of the Sost gene in this study. We injected Sost-attB plasmid with or without ΦC31 integrase plasmid into the mouse tail vein using a hydrodynamic-based method. The site-specific integration of the Sost gene into the mouse genome was confirmed by examining a pseudo-attP site on the hepatic genomic DNA. Sclerostin was expressed in the hepatocytes, secreted into the blood flow, and maintained at high concentrations in the mice with both Sost-attB plasmid and ΦC31 integrase plasmid injections, which was observed by serial measurement. Moreover, the mice with long-term high levels of serum sclerostin showed trabecular bone loss on micro-CT analysis. Peripheral B cell populations were not affected. Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the ΦC31 integrase system, leading to trabecular bone loss. These findings may help to further ascertain the effects of sclerostin introduced exogenously on the skeleton.",
author = "Dongdong Zhang and Park, {Bo Mi} and Myengmo Kang and Nam, {Hee Jin} and Kim, {Eun Jin} and Bae, {Chu Hyun} and Sungkil Lim",
year = "2016",
month = "4",
day = "8",
doi = "10.1016/j.bbrc.2016.01.178",
language = "English",
volume = "472",
pages = "471--476",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

The systemic effects of sclerostin overexpression using Φc31 integrase in mice. / Zhang, Dongdong; Park, Bo Mi; Kang, Myengmo; Nam, Hee Jin; Kim, Eun Jin; Bae, Chu Hyun; Lim, Sungkil.

In: Biochemical and Biophysical Research Communications, Vol. 472, No. 3, 08.04.2016, p. 471-476.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The systemic effects of sclerostin overexpression using Φc31 integrase in mice

AU - Zhang, Dongdong

AU - Park, Bo Mi

AU - Kang, Myengmo

AU - Nam, Hee Jin

AU - Kim, Eun Jin

AU - Bae, Chu Hyun

AU - Lim, Sungkil

PY - 2016/4/8

Y1 - 2016/4/8

N2 - Sclerostin, encoded by the Sost gene, is mainly produced by osteocytes in bone and antagonizes the Wnt/β-catenin signaling pathway, which is a requisite for bone formation. Currently, human anti-sclerostin antibodies are being tested in phase III clinical trials. In addition, serum sclerostin levels are reported to be associated with bone mineral density and fracture risk in normal individuals; however, the correlation between serum sclerostin and bone mass remains controversial. To study the effects of the continuous exposure of exogenous sclerostin on bone, a ΦC31 integrase system, which has the characteristics of site-specificity and efficiency, was applied for the delivery of the Sost gene in this study. We injected Sost-attB plasmid with or without ΦC31 integrase plasmid into the mouse tail vein using a hydrodynamic-based method. The site-specific integration of the Sost gene into the mouse genome was confirmed by examining a pseudo-attP site on the hepatic genomic DNA. Sclerostin was expressed in the hepatocytes, secreted into the blood flow, and maintained at high concentrations in the mice with both Sost-attB plasmid and ΦC31 integrase plasmid injections, which was observed by serial measurement. Moreover, the mice with long-term high levels of serum sclerostin showed trabecular bone loss on micro-CT analysis. Peripheral B cell populations were not affected. Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the ΦC31 integrase system, leading to trabecular bone loss. These findings may help to further ascertain the effects of sclerostin introduced exogenously on the skeleton.

AB - Sclerostin, encoded by the Sost gene, is mainly produced by osteocytes in bone and antagonizes the Wnt/β-catenin signaling pathway, which is a requisite for bone formation. Currently, human anti-sclerostin antibodies are being tested in phase III clinical trials. In addition, serum sclerostin levels are reported to be associated with bone mineral density and fracture risk in normal individuals; however, the correlation between serum sclerostin and bone mass remains controversial. To study the effects of the continuous exposure of exogenous sclerostin on bone, a ΦC31 integrase system, which has the characteristics of site-specificity and efficiency, was applied for the delivery of the Sost gene in this study. We injected Sost-attB plasmid with or without ΦC31 integrase plasmid into the mouse tail vein using a hydrodynamic-based method. The site-specific integration of the Sost gene into the mouse genome was confirmed by examining a pseudo-attP site on the hepatic genomic DNA. Sclerostin was expressed in the hepatocytes, secreted into the blood flow, and maintained at high concentrations in the mice with both Sost-attB plasmid and ΦC31 integrase plasmid injections, which was observed by serial measurement. Moreover, the mice with long-term high levels of serum sclerostin showed trabecular bone loss on micro-CT analysis. Peripheral B cell populations were not affected. Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the ΦC31 integrase system, leading to trabecular bone loss. These findings may help to further ascertain the effects of sclerostin introduced exogenously on the skeleton.

UR - http://www.scopus.com/inward/record.url?scp=84960385884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960385884&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.01.178

DO - 10.1016/j.bbrc.2016.01.178

M3 - Article

VL - 472

SP - 471

EP - 476

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -